Company: RNGE
Filing Date: 2025-11-19
Form Type: 424B3
Source: 0001493152-25-024206
Chunk: 25

Company: RANGE IMPACT, INC.
Filing Date: 2025-11-19
Form: 424B3
Chunk 25
---
5,602,484 |   |

4. DISPOSALS AND DISCONTINUED OPERATIONS

On August 22, 2024, substantially all the assets of Collins Building were sold to its previous owner in exchange for the cancellation of all remaining debt owed to him arising from the Company’s acquisition in August 2023. The Company recognized a net loss of $3,043,799 on the sale of the Collins Building assets. This sale does not constitute a discontinued operation as the Company has ongoing activities related to its acquisition of Collins Building, and only certain assets were sold and debts forgiven. As of March 31, 2025, any remaining active projects related to Collins Building will be completed by the previous owner or his subcontractors at the previous owner’s expense.

On September 30, 2024, the Company sold all of the common stock of Graphium Biosciences, Inc., its wholly-owned subsidiary, to a newly-formed entity, Placer Biosciences, Inc. (“Placer”), owned by two former officers of the Company, in exchange for a warrant to purchase 1,000 shares of Placer’s common stock (then representing 25% of the outstanding shares of Placer) at $0.01 per share and cash proceeds of $100. The warrant to purchase shares of Placer’s common stock expires on September 30, 2034.

Loss from Discontinued Operations

Discontinued operations for the three and nine months ended September 30, 2024 consists of results from Graphium Biosciences operations. The Company had no discontinued operations for either the three or nine months ended September 30, 2025. The following table provides details about the major classes of line items constituting “Loss from discontinued operations” presented on the Company’s Consolidated Statements of Operations:

SCHEDULE OF DISCONTINUING OPERATIONS INCOME STATEMENT

|                                   |     |   | Three Months Ended September 30, 
                             2024 |   |     |   | Nine Months Ended September 30, 
                            2024 |   |
|:----------------------------------|:----|:--|---------------------------------:|:--|:----|:--|--------------------------------:|:--|
| Operating expenses:               |     |   |                                  |   |     |   |                                 |   |
| Research and development          |     | $ |                          177,015 |   |     | $ |                         465,933 |   |
| Total operating expenses          |